Jump to content
Powered by

Business news from the BioRegionUlm

Three companies of the Ulm BioRegion have recently announced successful achievements: Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation for an anti-AIDS drug; ratiopharm announced the signing of discount agreements with ten public health insurance companies (AOK) and the Hartmann Group reported the acquisition of Kneipp.

Full marketing authorisation

Boehringer Ingelheim has received full marketing authorisation from the European Medicines Agency (EMEA) for its HIV protease inhibitor Aptivus® (tipranavir). The drug is indicated for the suppression of HIV in AIDS patients (HIV 1) who have developed resistance to other protease inhibitors.

The decision to grant full marketing authorisation was taken on the basis of two large trials involving 1,400 volunteers. The AIDS drug was approved by EMEA in 2005 under “extraordinary circumstances”. In the same year, the substance received accelerated marketing authorisation in the USA and the FDA granted traditional approval for Aptivus® on 4th October 2007. Additional marketing authorisations from different countries are expected in the “near future”.

Kneipp now fully-owned HARTMANN subsidiary

src=
On 1st April 2008, HARTMANN acquired 20 per cent of Kneipp shares from Susanne Boecker. This makes Kneipp a fully-owned subsidiary of Hartmann.

Hartmann acquired an 80 per cent stake in Kneipp in 2001, which at that time was looking for a strategic investor. The well-established Würzburg-based international company, which is dedicated to the natural healing principles of its founder, Sebastian Kneipp, produces medicine and nutritional supplements as well as body care and bath products. The Kneipp brand was revamped in recent years and made more attractive by redesigning the range of products.

ratiopharm signs discount agreements with ten German public health insurance companies (AOK)

src=

The Ulm producer of generic drugs, ratiopharm, has signed discount agreements for over 1,450 drugs in almost all fields of medication with ten German public health insurance companies. According to information from the company, these companies are located in Baden-Württemberg, Bavaria, Berlin, Mecklenburg-Western Pomerania, Lower Saxony, Rhineland-Palatinate, Saarland, Saxony-Anhalt, Saxony/Thuringia and Westphalia-Lippe.

The agreements benefit almost 20 million insured people. According to the company, 950 of the discounted drugs are fully recompensed by the insurance companies. The agreements will come into effect immediately. The agreements signed between ratiopharm and all German AOKs in January 2008 remain valid. 

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/business-news-from-the-bioregionulm